Form 4: Apellis Pharmaceuticals Executive James Chopas Reports Stock Transactions

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, reports the sale of 715 shares and the acquisition of 12,591 restricted stock units.

Summary

• James Chopas, VP/Chief Accounting Officer at Apellis Pharmaceuticals, sold 715 shares of common stock on January 17, 2025, at a price of $29.9582 per share.
• The sale was to cover tax withholding obligations related to restricted stock units.
• On January 21, 2025, Mr. Chopas was granted 12,591 restricted stock units.
• These restricted stock units vest 25% annually over four years from the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of stock transactions, and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to executive stock transactions and is common for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedule of the restricted stock units is a common practice for executive compensation.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on the stock price, but is unlikely to be significant.
• The grant of restricted stock units is a standard part of executive compensation and is not expected to have a significant impact on stakeholders.

Key Dates

Keywords

Apellis Pharmaceuticals, insider trading, stock transaction, restricted stock units, Form 4, executive compensation